The era of chemotherapy and IV tubes has given way to pills and outpatient monitoring. For patients with CML, the pill ...

Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

Findings further demonstrate the effectiveness of Roche's approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline signals progress ...

Developed by Ascentage Pharma, lisaftoclax is an orally available Bcl-2 inhibitor. Early data from the studies have demonstrated effects on hematologic malignancies and solid tumors. Lisaftoclax is ...

Developed by Ascentage Pharma, olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent Biologics ...

In vitro studies have suggested that BTKi therapy can suppress NOTCH1 activation via B-cell receptor–NOTCH1 interactions, providing a mechanistic rationale for these clinical results.

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately ...

The AMPLIFY study [NCT03836261] did not include patients with del (17p), so that doublet is not relevant. The study that used ...

Minimal residual disease (MRD)-guided retreatment with anti-CD20 antibodies effectively lowers MRD levels and delays clinical relapse in patients with high-risk chronic lymphocytic leukemia (CLL), ...

Ianalumab targets the B-cell activating factor receptor (BAFR) and ibrutinib belongs to a class of therapeutics called Bruton ...